Cargando…
Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen
Alternative dosage regimens for some anticancer therapies have been proposed in the midst of the SARS-COV-2 pandemic in order to protect the patients from attending to health care facilities. Flat-dosing of several immune-checkpoint inhibitors (ICIs), including nivolumab, have been established. Alth...
Autores principales: | Pous, Anna, Izquierdo, Cristina, Cucurull, Marc, Sánchez, Silvia, Lezcano, Clara, Domenech, Marta, Llobera, Laia, Plaja, Andrea, Moran, Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107731/ https://www.ncbi.nlm.nih.gov/pubmed/34012801 http://dx.doi.org/10.21037/tlcr-20-1315 |
Ejemplares similares
-
Nivolumab: Immune-related meningoencephalitis: case report
Publicado: (2021) -
Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?
por: Plaja, Andrea, et al.
Publicado: (2021) -
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
por: Shields, Lisa B.E., et al.
Publicado: (2021) -
Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
por: Zhao, X., et al.
Publicado: (2017) -
Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers
por: Bei, Di, et al.
Publicado: (2020)